AI Summary
We reviewed 6 live results for stelara (ustekinumab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Immunology.
Comparison Table
Recommended
Stelara (ustekinumab)
Source: Janssen
Description
Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion.
Best for
pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management
View Details
Rating
Pyzchiva (ustekinumab-ttwe)
Source: Sandoz
Description
Pyzchiva is an FDA-approved interchangeable biosimilar to Stelara, designed for the treatment of various chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Available in subcutaneous pre-filled syringes and intravenous single-dose vials, it provides a therapeutic alternative with the same clinical efficacy and safety as the originator biologic.
Best for
cost-effective biologic therapy, plaque psoriasis management, interchangeable drug substitution and Crohn's disease patients
View Details
Rating
Epyztek (ustekinumab)
Source: Samsung Bioepis
Description
Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara.
Best for
patients in South Korea, psoriasis treatment and local biosimilar seekers
View Details
Rating
| Compare | Stelara (ustekinumab) | Pyzchiva (ustekinumab-ttwe) | Epyztek (ustekinumab) |
|---|---|---|---|
| Source | Janssen | Sandoz | Samsung Bioepis |
| Description | Stelara is the originator ustekinumab biologic, a human interleukin-12 and -23 antagonist. In Singapore, it is HSA-registered for treating plaque psoriasis in both adults and children, as well as psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is delivered via subcutaneous injection or intravenous infusion. | Pyzchiva is an FDA-approved interchangeable biosimilar to Stelara, designed for the treatment of various chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Available in subcutaneous pre-filled syringes and intravenous single-dose vials, it provides a therapeutic alternative with the same clinical efficacy and safety as the originator biologic. | Epyztek is the South Korean market brand for the ustekinumab biosimilar developed by Samsung Bioepis. Indicated for patients with psoriasis and other autoimmune conditions, it provides a high-quality local alternative to the originator product, Stelara. |
| Best for | pediatric psoriasis patients, Singapore-based healthcare users, established biologic treatment and ulcerative colitis management | cost-effective biologic therapy, plaque psoriasis management, interchangeable drug substitution and Crohn's disease patients | patients in South Korea, psoriasis treatment and local biosimilar seekers |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Stelara (ustekinumab) from Janssen."
I picked this because As the originator product with extensive clinical history and current HSA registration, Stelara is the standard of care for ustekinumab therapy in Singapore.
Share this search
Related Finds